Praxis Precision Medicines Inc
PRAX
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.33B
Close$
$15.87
95.3% downside
Current Fair Value
95.3% downsideOvervalued by 95.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.33 Billion |
|---|---|
| Enterprise Value | $8.85 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-13.48 |
| Beta | 2.78 |
| Outstanding Shares | 29,131,375 |
Return
| Return on Equity | -25.29% |
|---|---|
| Return on Assets | -24.40% |
| Return on Invested Capital | -27.55% |
Valuation & Multiples
| P/E Ratio | -25.84 |
|---|---|
| PEG | -145.93 |
| Price to Sales | - |
| Price to Book Ratio | 7.27 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -23.97 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-3.67
Average shareholder expectationRevenue Estimate
$1.25 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-3.53
Average shareholder expectationRevenue Estimate
$130,769
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 5.1066▲ 149.82% |
|---|---|
| Total Calls | 165,100▲ 4.96% |
| Total Puts | 843,100▲ 48.54% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 147.03%▲ 36.95% |
|---|---|
| Total Invested | $11.39B▲ 11.22% |
| Investors Holding | 330▲ 19.00% |
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...